Literature DB >> 25098287

Biochemical signaling of PD-1 on T cells and its functional implications.

Vassiliki A Boussiotis1, Pranam Chatterjee, Lequn Li.   

Abstract

Maintenance of peripheral tolerance is essential for homeostasis of the immune system. While central tolerance mechanisms result in deletion of the majority of self-reactive T cells, T lymphocytes specific for self-antigens also escape this process and circulate in the periphery. To control the development of autoimmunity, multiple mechanisms of peripheral tolerance have evolved, including T cell anergy, deletion, and suppression by regulatory T (Treg) cells. The pathway consisting of the programmed cell death 1 (PD-1) receptor (CD279) and its ligands PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC; CD273) plays a vital role in the induction and maintenance of peripheral tolerance. This pathway also regulates the balance between stimulatory and inhibitory signals needed for effective immunity and maintenance of T cell homeostasis. In contrast to this important beneficial role in maintaining T cell homeostasis, PD-1 mediates potent inhibitory signals that prevent the expansion and function of T effector cells and have detrimental effects on antiviral and antitumor immunity. Despite the compelling studies on the significant functional role of PD-1 in mediating inhibition of activated T cells, little is known about how PD-1 blocks T cell activation. Here, we will provide a brief overview of the signaling events that are regulated by PD-1 triggering, and we will discuss their implications on cell intrinsic and extrinsic mechanisms that determine the fate and function of T effector cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25098287      PMCID: PMC4151049          DOI: 10.1097/PPO.0000000000000059

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  79 in total

1.  In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability.

Authors:  J C Rathmell; M G Vander Heiden; M H Harris; K A Frauwirth; C B Thompson
Journal:  Mol Cell       Date:  2000-09       Impact factor: 17.970

Review 2.  Chromatin remodeling and Rb activity.

Authors:  J W Harbour; D C Dean
Journal:  Curr Opin Cell Biol       Date:  2000-12       Impact factor: 8.382

3.  Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4.

Authors:  Hans Christian Probst; Kathy McCoy; Taku Okazaki; Tasuku Honjo; Maries van den Broek
Journal:  Nat Immunol       Date:  2005-01-30       Impact factor: 25.606

4.  Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.

Authors:  Nikolaos Patsoukis; Julia Brown; Victoria Petkova; Fang Liu; Lequn Li; Vassiliki A Boussiotis
Journal:  Sci Signal       Date:  2012-06-26       Impact factor: 8.192

5.  IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity.

Authors:  Seigo Terawaki; Shunsuke Chikuma; Shiro Shibayama; Tamon Hayashi; Takao Yoshida; Taku Okazaki; Tasuku Honjo
Journal:  J Immunol       Date:  2011-01-24       Impact factor: 5.422

6.  Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets.

Authors:  Ryan D Michalek; Valerie A Gerriets; Sarah R Jacobs; Andrew N Macintyre; Nancie J MacIver; Emily F Mason; Sarah A Sullivan; Amanda G Nichols; Jeffrey C Rathmell
Journal:  J Immunol       Date:  2011-02-11       Impact factor: 5.422

7.  Posttranscriptional control of T cell effector function by aerobic glycolysis.

Authors:  Chih-Hao Chang; Jonathan D Curtis; Leonard B Maggi; Brandon Faubert; Alejandro V Villarino; David O'Sullivan; Stanley Ching-Cheng Huang; Gerritje J W van der Windt; Julianna Blagih; Jing Qiu; Jason D Weber; Edward J Pearce; Russell G Jones; Erika L Pearce
Journal:  Cell       Date:  2013-06-06       Impact factor: 41.582

8.  A diacylglycerol-protein kinase C-RasGRP1 pathway directs Ras activation upon antigen receptor stimulation of T cells.

Authors:  Jeroen P Roose; Marianne Mollenauer; Vikas A Gupta; James Stone; Arthur Weiss
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

9.  PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A.

Authors:  Nikolaos Patsoukis; Duygu Sari; Vassiliki A Boussiotis
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

10.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

Authors:  Tadashi Yokosuka; Masako Takamatsu; Wakana Kobayashi-Imanishi; Akiko Hashimoto-Tane; Miyuki Azuma; Takashi Saito
Journal:  J Exp Med       Date:  2012-05-28       Impact factor: 14.307

View more
  64 in total

1.  NLRX1 Regulates Effector and Metabolic Functions of CD4+ T Cells.

Authors:  Andrew Leber; Raquel Hontecillas; Nuria Tubau-Juni; Victoria Zoccoli-Rodriguez; Matthew Hulver; Ryan McMillan; Kristin Eden; Irving C Allen; Josep Bassaganya-Riera
Journal:  J Immunol       Date:  2017-02-03       Impact factor: 5.422

Review 2.  Targeting the programmed death-1 pathway in lymphoid neoplasms.

Authors:  Chi Young Ok; Ken H Young
Journal:  Cancer Treat Rev       Date:  2017-02-11       Impact factor: 12.111

3.  Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.

Authors:  S Alice Long; Jerill Thorpe; Kevan C Herold; Mario Ehlers; Srinath Sanda; Noha Lim; Peter S Linsley; Gerald T Nepom; Kristina M Harris
Journal:  Cell Immunol       Date:  2017-08-18       Impact factor: 4.868

Review 4.  Helicobacter pylori Deregulates T and B Cell Signaling to Trigger Immune Evasion.

Authors:  Victor E Reyes; Alex G Peniche
Journal:  Curr Top Microbiol Immunol       Date:  2019       Impact factor: 4.291

5.  Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.

Authors:  Tan-Huy Chu; Manh-Cuong Vo; Hye-Seong Park; Thangaraj Jaya Lakshmi; Sung-Hoon Jung; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Cancer Immunol Immunother       Date:  2020-07-04       Impact factor: 6.968

6.  Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy.

Authors:  Kevin G Shim; Shane Zaidi; Jill Thompson; Tim Kottke; Laura Evgin; Karishma R Rajani; Matthew Schuelke; Christopher B Driscoll; Amanda Huff; Jose S Pulido; Richard G Vile
Journal:  Mol Ther       Date:  2017-02-22       Impact factor: 11.454

Review 7.  Targeting T cell metabolism for therapy.

Authors:  David O'Sullivan; Erika L Pearce
Journal:  Trends Immunol       Date:  2015-01-15       Impact factor: 16.687

Review 8.  Genetic and Epigenetic Regulation of PD-1 Expression.

Authors:  Alexander P R Bally; James W Austin; Jeremy M Boss
Journal:  J Immunol       Date:  2016-03-15       Impact factor: 5.422

9.  PD-L1 is required for human endometrial regenerative cells-associated attenuation of experimental colitis in mice.

Authors:  Ganggang Shi; Grace Wang; Shanzheng Lu; Xiang Li; Baoren Zhang; Xiaoxi Xu; Xu Lan; Yiming Zhao; Hao Wang
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

Review 10.  The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.

Authors:  A A Gru; B H Haverkos; A G Freud; J Hastings; N B Nowacki; C Barrionuevo; C E Vigil; R Rochford; Y Natkunam; R A Baiocchi; P Porcu
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.